Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Century Therapeutics (NASDAQ: IPSC) reported significant progress in Q1 2025, highlighted by the initiation of patient dosing in the Phase 1 CALiPSO-1 trial for CNTY-101 in autoimmune disease. The company has expanded its clinical trial sites to Europe, with CTA authorizations in Germany, France, and Italy. The CARAMEL investigator-initiated trial is set to begin in mid-2025.
The company's lead preclinical program, CNTY-308, is scheduled to enter IND-enabling studies in mid-2025. At ASGCT's 28th Annual Meeting, Century showcased its preclinical pipeline featuring iPSC-derived 'tunable' CD4+/CD8+ ab T cells and Allo-Evasion鈩� 5.0 technology.
Financially, Century reported $185.8 million in cash and equivalents, expected to fund operations into Q4 2026. Q1 2025 saw $109.2 million in collaboration revenue following the termination of its Bristol-Myers Squibb agreement. The company posted a net income of $76.6 million, compared to a $28.1 million loss in Q1 2024.
Century Therapeutics (NASDAQ: IPSC) ha riportato progressi significativi nel primo trimestre del 2025, evidenziati dall'inizio della somministrazione ai pazienti nella sperimentazione di Fase 1 CALiPSO-1 per CNTY-101 nelle malattie autoimmuni. L'azienda ha ampliato i siti di sperimentazione clinica in Europa, ottenendo le autorizzazioni CTA in Germania, Francia e Italia. Lo studio CARAMEL, avviato da investigatori, 猫 previsto per met脿 2025.
Il principale programma preclinico dell'azienda, CNTY-308, 猫 programmato per entrare negli studi abilitanti IND a met脿 2025. Alla 28陋 Riunione Annuale dell'ASGCT, Century ha presentato la sua pipeline preclinica con cellule ab T CD4+/CD8+ 'regolabili' derivate da iPSC e la tecnologia Allo-Evasion鈩� 5.0.
Dal punto di vista finanziario, Century ha riportato 185,8 milioni di dollari in liquidit脿 e equivalenti, sufficienti a finanziare le operazioni fino al quarto trimestre del 2026. Nel primo trimestre 2025 ha registrato 109,2 milioni di dollari di ricavi da collaborazioni dopo la cessazione dell'accordo con Bristol-Myers Squibb. L'azienda ha chiuso con un utile netto di 76,6 milioni di dollari, rispetto a una perdita di 28,1 milioni nel primo trimestre 2024.
Century Therapeutics (NASDAQ: IPSC) report贸 avances significativos en el primer trimestre de 2025, destacando el inicio de la dosificaci贸n de pacientes en el ensayo de Fase 1 CALiPSO-1 para CNTY-101 en enfermedades autoinmunes. La compa帽铆a ha ampliado sus sitios de ensayo cl铆nico a Europa, con autorizaciones CTA en Alemania, Francia e Italia. El ensayo iniciado por investigadores CARAMEL est谩 programado para comenzar a mediados de 2025.
El programa precl铆nico principal de la compa帽铆a, CNTY-308, est谩 previsto para iniciar estudios habilitantes IND a mediados de 2025. En la 28陋 Reuni贸n Anual de ASGCT, Century mostr贸 su pipeline precl铆nico con c茅lulas ab T CD4+/CD8+ 'ajustables' derivadas de iPSC y la tecnolog铆a Allo-Evasion鈩� 5.0.
En t茅rminos financieros, Century report贸 185,8 millones de d贸lares en efectivo y equivalentes, suficientes para financiar operaciones hasta el cuarto trimestre de 2026. En el primer trimestre de 2025 registr贸 109,2 millones de d贸lares en ingresos por colaboraciones tras la terminaci贸n de su acuerdo con Bristol-Myers Squibb. La compa帽铆a report贸 un ingreso neto de 76,6 millones de d贸lares, comparado con una p茅rdida de 28,1 millones en el primer trimestre de 2024.
Century Therapeutics(NASDAQ: IPSC)電� 2025雲� 1攵勱赴鞐� 欷戩殧頃� 歆勳爠鞚� 氤搓碃頄堨溂氅�, 鞛愱皜氅挫棴 歆堩櫂 旃橂鞝� CNTY-101鞚� 1靸� CALiPSO-1 鞛勳儊鞁滍棙鞐愳劀 頇橃瀽 韴棳毳� 鞁滌瀾頃� 鞝愳澊 欤茧霅╇媹雼�. 須岇偓電� 鞛勳儊鞁滍棙 鞛レ唽毳� 鞙犽熃鞙茧 頇曥灔頃橃棳 霃呾澕, 頂勲瀾鞀�, 鞚错儓毽晞鞐愳劀 CTA 鞀轨澑鞚� 氚涭晿鞀惦媹雼�. 鞐瓣惮鞛愱皜 鞁滌瀾頃橂姅 CARAMEL 鞁滍棙鞚� 2025雲� 欷戨皹鞐� 鞁滌瀾霅� 鞓堨爼鞛呺媹雼�.
須岇偓鞚� 欤检殧 鞝勳瀯靸� 頂勲攴鸽灗鞚� CNTY-308鞚� 2025雲� 欷戨皹鞐� IND 鞀轨澑 鞐瓣惮鞐� 霌れ柎臧� 鞓堨爼鞛呺媹雼�. ASGCT 鞝�28彀� 鞐半須岇潣鞐愳劀 Century電� iPSC 鞙犽灅鞚� '臁办爤 臧�電ロ暅' CD4+/CD8+ ab T 靹疙彫鞕� Allo-Evasion鈩� 5.0 旮办垹鞚� 韽暔頃� 鞝勳瀯靸� 韺岇澊頂勲澕鞚胳潉 靹犽炒鞓�鞀惦媹雼�.
鞛鞝侅溂搿� Century電� 1鞏� 8580毵� 雼煬鞚� 順勱笀 氚� 順勱笀靹� 鞛愳偘鞚� 氤搓碃頄堨溂氅�, 鞚措姅 2026雲� 4攵勱赴旯岇 鞖挫榿 鞛愱笀鞚� 歆�鞗愴暊 瓴冹溂搿� 鞓堨儊霅╇媹雼�. 2025雲� 1攵勱赴鞐愲姅 Bristol-Myers Squibb 瓿勳暯 膦呺 頉� 順戨牓 靾橃澋鞙茧 1鞏� 920毵� 雼煬毳� 旮半頄堨姷雼堧嫟. 須岇偓電� 2024雲� 1攵勱赴 2810毵� 雼煬 靻愳嫟瓿� 牍勱祼頃� 7660毵� 雼煬鞚� 靾滌澊鞚奠潉 旮半頄堨姷雼堧嫟.
Century Therapeutics (NASDAQ : IPSC) a annonc茅 des progr猫s significatifs au premier trimestre 2025, marqu茅s par le d茅but de l'administration aux patients dans l'essai de phase 1 CALiPSO-1 pour CNTY-101 dans les maladies auto-immunes. La soci茅t茅 a 茅tendu ses sites d'essais cliniques en Europe, avec des autorisations CTA en Allemagne, en France et en Italie. L'essai initi茅 par les chercheurs CARAMEL devrait d茅buter 脿 la mi-2025.
Le programme pr茅clinique principal de la soci茅t茅, CNTY-308, doit entrer dans les 茅tudes pr茅paratoires IND 脿 la mi-2025. Lors de la 28e r茅union annuelle de l'ASGCT, Century a pr茅sent茅 sa pipeline pr茅clinique comprenant des cellules T ab CD4+/CD8+ 芦 modulables 禄 d茅riv茅es de iPSC et la technologie Allo-Evasion鈩� 5.0.
Sur le plan financier, Century a d茅clar茅 185,8 millions de dollars en liquidit茅s et 茅quivalents, ce qui devrait financer ses op茅rations jusqu'au quatri猫me trimestre 2026. Le premier trimestre 2025 a g茅n茅r茅 109,2 millions de dollars de revenus de collaboration suite 脿 la r茅siliation de son accord avec Bristol-Myers Squibb. La soci茅t茅 a enregistr茅 un b茅n茅fice net de 76,6 millions de dollars, contre une perte de 28,1 millions au premier trimestre 2024.
Century Therapeutics (NASDAQ: IPSC) berichtete 眉ber bedeutende Fortschritte im ersten Quartal 2025, insbesondere 眉ber den Beginn der Patientendosierung in der Phase-1-Studie CALiPSO-1 f眉r CNTY-101 bei Autoimmunerkrankungen. Das Unternehmen hat seine klinischen Studienstandorte nach Europa ausgeweitet und erhielt CTA-Genehmigungen in Deutschland, Frankreich und Italien. Die von Forschern initiierte CARAMEL-Studie soll Mitte 2025 starten.
Das f眉hrende pr盲klinische Programm des Unternehmens, CNTY-308, soll Mitte 2025 in IND-f盲hige Studien eintreten. Auf der 28. Jahrestagung der ASGCT pr盲sentierte Century seine pr盲klinische Pipeline mit iPSC-abgeleiteten, "einstellbaren" CD4+/CD8+ ab T-Zellen und der Allo-Evasion鈩� 5.0-Technologie.
Finanziell meldete Century 185,8 Millionen US-Dollar in bar und 脛quivalenten, was voraussichtlich die Betriebskosten bis zum vierten Quartal 2026 deckt. Im ersten Quartal 2025 erzielte das Unternehmen 109,2 Millionen US-Dollar an Kooperationsums盲tzen nach Beendigung der Vereinbarung mit Bristol-Myers Squibb. Das Unternehmen verzeichnete einen Nettogewinn von 76,6 Millionen US-Dollar, im Vergleich zu einem Verlust von 28,1 Millionen im ersten Quartal 2024.
- Net income of $76.6 million in Q1 2025, compared to a loss of $28.1 million in Q1 2024
- Strong cash position of $185.8 million, providing runway into Q4 2026
- Successful expansion of clinical trials to Europe with CTA authorizations in Germany, France, and Italy
- Recognition of $109.2 million in collaboration revenue from Bristol-Myers Squibb agreement
- Termination of Bristol-Myers Squibb Collaboration Agreement, eliminating future collaboration revenues
- Increased R&D expenses to $26.6 million from $23.4 million year-over-year
Insights
Century Therapeutics shows promising clinical progress with CNTY-101 and pipeline advancement, while posting strong Q1 financials following BMS collaboration termination.
Century Therapeutics is making solid clinical progress with its lead program CNTY-101, with patient dosing now underway in the U.S. for the CALiPSO-1 trial in B-cell-mediated autoimmune diseases. The regulatory authorizations in Germany, France, and Italy represent significant external validation of their iPSC-derived cell therapy approach. This European expansion should accelerate patient recruitment, with five U.S. trial sites already active and more planned for 2025.
The company's preclinical pipeline is also advancing, with CNTY-308 (a CD19-targeted CD4+/CD8+ ab CAR-iT cell therapy) on track to enter IND-enabling studies by mid-2025. Their presentations at ASGCT highlight important technological advances in their platform, particularly with their proprietary Allo-Evasion鈩� 5.0 technology designed to evade multiple immune system components.
Financially, Century reported a
The R&D expenses increased by approximately
The projected clinical readout for CNTY-101 by year-end 2025 represents a critical upcoming catalyst. Success would validate their iPSC-derived approach and potentially position Century as a leader in off-the-shelf cell therapy. While the termination of the BMS collaboration could initially appear concerning, the financial windfall and streamlined pipeline control may ultimately benefit Century's long-term strategic positioning.
- Patient dosing initiated in Phase 1 CALiPSO-1 trial evaluating CNTY-101 in autoimmune disease; expanding to additional U.S. and European sites following CTA authorizations in Germany, France, and Italy
- CNTY-308 expected to enter IND-enabling studies in mid-2025 to support anticipated clinical trials in B-cell-mediated autoimmune diseases and malignancies
- Presentations at ASGCT 28th Annual Meeting highlight preclinical pipeline anchored by advanced iPSC-derived 鈥檛unable鈥� CD4+/CD8+ ab T cells and Allo-Evasion鈩� 5.0 technology
PHILADELPHIA, May 15, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (鈥楥entury鈥�, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today reported financial results and business highlights for the first quarter ended March 31, 2025.
鈥淲e have made important progress focusing on pipeline programs with transformational potential in high-value commercial markets. In a recently held company webinar and at ASGCT, we showcased developmental progress with our preclinical pipeline, iPSC platform, and manufacturing capabilities, highlighting the potential for a pathway to developing iPSC-derived cell therapies at antibody-like scale. We are on track to initiate IND-enabling studies for our lead preclinical program, CNTY-308, in mid-2025,鈥� said Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century Therapeutics. 鈥淔or our clinical-stage pipeline, patient dosing is now underway in the U.S. for the CALiPSO-1 trial and, with expansion into Europe, we remain on track to deliver clinical data for CNTY-101 by the end of 2025. We look forward to building on this momentum and pursuing a disciplined approach across our pipeline to bring investigational cell therapies closer to patients and generate value for all our stakeholders.鈥�
First Quarter 2025 and Recent Highlights
CNTY-101 in Autoimmune Disease
- Patient dosing underway in CALiPSO-1 trial in the U.S.: In March 2025, the first patient was dosed in the Phase 1 CALiPSO-1 trial which is currently evaluating CNTY-101 as a potential treatment for patients with B-cell-mediated autoimmune diseases.
- Focus on CALiPSO-1 clinical trial expansion and patient recruitment: Five clinical trial sites in the U.S. are active with additional U.S. clinical trial sites expected to open in 2025. Site activation activities are underway in select European countries, with enrollment at these sites expected to initiate in the second half of 2025. The company鈥檚 Clinical Trial Application (CTA) has been authorized in Germany, France, and Italy, providing important external validation of Century鈥檚 approach to clinical studies with allogeneic iPSC-derived therapies.
- CARAMEL IIT CTA authorized and study on track to commence in mid-2025: The CARAMEL investigator-initiated trial (IIT), a Phase 1/2 trial of CNTY-101 in patients with B-cell-mediated autoimmune diseases led by Professors Georg Schett and Andreas Mackensen and sponsored by the Friedrich-Alexander University Erlangen-N眉rnberg, is expected to commence in mid-2025. The CTA has been authorized in Germany
- Clinical data by end of 2025: The company remains on track to report clinical data for CNTY-101 by the end of 2025.
CNTY-308 and Other Preclinical Programs
- ASGCT presentations highlighting preclinical pipeline: At the ongoing American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, the company is presenting data on the company鈥檚 emerging preclinical cell therapy pipeline for autoimmune diseases and cancer. The data from the poster presentation suggest certain engineering modifications to CAR-iT and CAR-iNK cells can improve the anti-tumor activity of iPSC-derived immunotherapies to withstand the immunosuppressive nature of the solid tumor microenvironment. The data from the oral presentation characterize the generation of allogeneic iPSC-derived targeted CD4+/CD8+ ab CAR-T cells with comparable function, in vivo proliferation, and tumor control to primary T cells, supporting their use for the development of scalable, accessible CAR-T cell therapies.
- CNTY-308 on track to enter into IND-enabling studies in mid-2025: The company continues to expect to initiate Investigational New Drug (IND)-enabling studies with CNTY-308, a CD19-targeted CD4+/CD8+ ab CAR-iT cell therapy engineered with Allo-Evasion鈩� 5.0 as a potential treatment for B-cell-mediated autoimmune diseases and malignancies, in mid-2025.
- Progressing early-stage development activities for iPSC-derived ab CAR-T cells in oncology and opportunities with non-immune effector cells in high-impact diseases: The company is advancing CNTY-341, a CD19/CD22 dual-targeted CAR-iT investigational cell therapy intended for B-cell malignancies, and the company鈥檚 first solid tumor CAR-iT investigational program exploiting nectin-4 CAR and other validated targets. Each of these programs is anchored by advanced iPSC-derived 鈥檛unable鈥� CD4+/CD8+ ab T cells and is engineered with the company鈥檚 proprietary immune evasion technology, Allo-Evasion鈩� 5.0, which is designed to enable holistic evasion of T cell, NK cell, and humoral immunity. In addition, the company is leveraging its deep expertise in selective iPSC differentiation to non-immune effector cells with opportunities to potentially accelerate in high-impact therapeutic areas where the company believes its technology and capabilities provide meaningful differentiation.
First Quarter 2025 Financial Results
- Cash Position: Cash, cash equivalents, and marketable securities were
$185.8 million as of March 31, 2025, as compared to$220.1 million as of December 31, 2024. The company estimates its cash, cash equivalents, and investments will support operations into the fourth quarter of 2026.
- Collaboration Revenue: Collaboration revenue generated through the company鈥檚 collaboration, option, and license agreement with Bristol-Myers Squibb (the Collaboration Agreement) was
$109.2 million for the three months ended March 31, 2025, compared to$0.9 million for the same period in 2024. The Collaboration Agreement was terminated effective March 12, 2025. As such, the company recognized$109.2 million of collaboration revenue for the quarter ended March 31, 2025. There will be no future collaboration revenues recognized under the Collaboration Agreement.
- Research and Development (R&D) Expenses: R&D expenses were
$26.6 million for the three months ended March 31, 2025, compared to$23.4 million for the same period in 2024. The increase in R&D expenses is most notably due to increased clinical trial costs and advancing of preclinical programs.
- General and Administrative (G&A) Expenses: G&A expenses were
$8.4 million for the three months ended March 31, 2025, compared to$8.7 million for the same period in 2024. The decrease was primarily due to a decrease in salary and benefit expense.
- Net Income (Loss): Net income was
$76.6 million for the three months ended March 31, 2025, compared to net (loss) of$28.1 million for the same period in 2024.
About Century Therapeutics
Century Therapeutics (NASDAQ: IPSC) is a clinical-stage biotechnology company leveraging its expertise in cellular reprogramming, genetic engineering, and manufacturing to develop cell therapies with the potential to provide meaningful advantages over existing cell therapies. Century鈥檚 genetically engineered, iPSC-derived cell therapy pipeline includes programs designed to address autoimmune diseases and cancers. Century believes its commitment to developing off-the-shelf cell therapies will expand patient access and provide an opportunity to advance the course of autoimmune disease and cancer care. For more information on Century Therapeutics, please visit听听and connect with us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding our clinical development plans and timelines are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as 鈥渕ay,鈥� 鈥渕ight,鈥� 鈥渨ill,鈥� 鈥渟hould,鈥� 鈥渆xpect,鈥� 鈥減lan,鈥� 鈥渁im,鈥� 鈥渟eek,鈥� 鈥渁nticipate,鈥� 鈥渃ould,鈥� 鈥渋ntend,鈥� 鈥渢arget,鈥� 鈥減roject,鈥� 鈥渃ontemplate,鈥� 鈥渂elieve,鈥� 鈥渆stimate,鈥� 鈥減redict,鈥� 鈥渇orecast,鈥� 鈥減otential鈥� or 鈥渃ontinue鈥� or the negative of these terms or other similar expressions. The forward-looking statements in this press release are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control, including, among others: our ability to successfully advance our current and future product candidates through development activities, preclinical studies, and clinical trials; our dependence on the success of our lead product candidate, CNTY-101; our ability to progress CNTY-101 through clinical development; our ability to meet development milestones on anticipated timelines; uncertainties inherent in the results of preliminary data, pre-clinical studies and earlier-stage clinical trials, which may not be predictive of final results or the results of later-stage clinical trials; our ability to obtain clearance of our future IND or CTA submissions and commence and complete clinical trials on expected timelines, or at all; our reliance on the maintenance of certain key collaborative relationships for the manufacturing and development of our product candidates; the timing, scope and likelihood of regulatory filings and approvals, including final regulatory approval of our product candidates; the impact of geopolitical issues, trade disputes and tariffs, banking instability and inflation on our business and operations, supply chain and labor force; the performance of third parties in connection with the development of our product candidates, including third parties conducting our clinical trials as well as third-party suppliers and manufacturers; our ability to successfully commercialize our product candidates and develop sales and marketing capabilities, if our product candidates are approved; our ability to recruit and maintain key members of management and our ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are described more fully in the 鈥淩isk Factors鈥� section of our most recent filings with the Securities and Exchange Commission and available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
For More Information:
Century Therapeutics
Morgan Conn, Ph.D.
Chief Financial Officer
JPA Health
Sarah McCabe
| Century Therapeutics, Inc | ||||||||
| Condensed Balance Sheets | ||||||||
| (unaudited, in thousands) | ||||||||
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||
| 听 | 听 | March 31, | 听 | December 31, | ||||
| Assets | 听 | 2025 | 听 | 2024 | ||||
| Current Assets: | 听 | $ | 听 | 听 | $ | 听 | ||
| Cash and cash equivalents | 听 | 听 | 51,865 | 听 | 听 | 听 | 58,441 | 听 |
| Short-term investments | 听 | 听 | 113,256 | 听 | 听 | 听 | 130,851 | 听 |
| Prepaid expenses and other current assets | 听 | 听 | 4,510 | 听 | 听 | 听 | 4,759 | 听 |
| Total current assets | 听 | 听 | 169,631 | 听 | 听 | 听 | 194,051 | 听 |
| Property and equipment, net | 听 | 听 | 59,532 | 听 | 听 | 听 | 62,141 | 听 |
| Operating lease right-of-use assets, net | 听 | 听 | 28,232 | 听 | 听 | 听 | 28,706 | 听 |
| Long-term investments | 听 | 听 | 20,713 | 听 | 听 | 听 | 30,818 | 听 |
| Intangible assets | 听 | 听 | 34,200 | 听 | 听 | 听 | 34,200 | 听 |
| Other long-term assets | 听 | 听 | 3,301 | 听 | 听 | 听 | 3,300 | 听 |
| Total assets | 听 | $ | 315,609 | 听 | 听 | $ | 353,216 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||
| Liabilities, convertible preferred stock, and stockholders' equity | 听 | 听 | 听 | |||||
| Current liabilities: | 听 | 听 | 听 | 听 | 听 | 听 | ||
| Accounts payable | 听 | $ | 3,573 | 听 | 听 | $ | 3,075 | 听 |
| Accrued expenses and other liabilities | 听 | 听 | 10,930 | 听 | 听 | 听 | 17,543 | 听 |
| Deferred revenue, current | 听 | 听 | - | 听 | 听 | 听 | 109,164 | 听 |
| Total current liabilities | 听 | 听 | 14,503 | 听 | 听 | 听 | 129,782 | 听 |
| Operating lease liability, noncurrent | 听 | 听 | 47,793 | 听 | 听 | 听 | 48,960 | 听 |
| Contingent consideration liability | 听 | 听 | 8,500 | 听 | 听 | 听 | 8,738 | 听 |
| Deferred tax liability | 听 | 听 | 4,374 | 听 | 听 | 听 | 4,374 | 听 |
| Total liabilities | 听 | 听 | 75,170 | 听 | 听 | 听 | 191,854 | 听 |
| Stockholders' equity | 听 | 听 | 听 | 听 | 听 | 听 | ||
| Common stock | 听 | 听 | 9 | 听 | 听 | 听 | 9 | 听 |
| Additional paid-in capital | 听 | 听 | 945,902 | 听 | 听 | 听 | 943,366 | 听 |
| Accumulated deficit | 听 | 听 | (705,777 | ) | 听 | 听 | (782,337 | ) |
| Accumulated other comprehensive loss | 听 | 听 | 305 | 听 | 听 | 听 | 324 | 听 |
| Total stockholders' equity | 听 | 听 | 240,439 | 听 | 听 | 听 | 161,362 | 听 |
| Total liabilities and stockholders' equity | 听 | $ | 315,609 | 听 | 听 | $ | 353,216 | 听 |
| Century Therapeutics, Inc | |||||||
| Condensed consolidated statements of operations | |||||||
| (unaudited, in thousands, except share and per share amounts) | |||||||
| 听 | 听 | 听 | 听 | 听 | 听 | ||
| 听 | Three Months Ended | 听 | Three Months Ended | ||||
| 听 | March 31, 2025 | 听 | March 31, 2024 | ||||
| Collaboration Revenue | $ | 109,164 | 听 | 听 | $ | 855 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | ||
| Operating Expenses | 听 | 听 | 听 | 听 | 听 | ||
| Research and development | 听 | 26,580 | 听 | 听 | 听 | 23,421 | 听 |
| General and administrative | 听 | 8,408 | 听 | 听 | 听 | 8,743 | 听 |
| Total operating expenses | 听 | 34,988 | 听 | 听 | 听 | 32,164 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | ||
| Income (loss) from operations | 听 | 74,176 | 听 | 听 | 听 | (31,309 | ) |
| 听 | 听 | 听 | 听 | 听 | 听 | ||
| Interest income | 听 | 2,422 | 听 | 听 | 听 | 3,237 | 听 |
| Other income (expense), net | 听 | (38 | ) | 听 | 听 | 11 | 听 |
| Income (loss) before provision for income taxes | 听 | 76,560 | 听 | 听 | 听 | (28,061 | ) |
| Provision for income taxes | 听 | - | 听 | 听 | 听 | (1 | ) |
| Net Income (loss) | $ | 76,560 | 听 | 听 | $ | (28,062 | ) |
| 听 | 听 | 听 | 听 | 听 | 听 | ||
| Unrealized loss on investments | 听 | (19 | ) | 听 | 听 | (351 | ) |
| Foreign currency translation gain | 听 | - | 听 | 听 | 听 | 2 | 听 |
| Comprehensive income (loss) | $ | 76,541 | 听 | 听 | $ | (28,411 | ) |
| 听 | 听 | 听 | 听 | 听 | 听 | ||
| Net income (loss) per common share: Basic | 听 | 0.89 | 听 | 听 | 听 | (0.45 | ) |
| Net income (loss) per common share: Diluted | 听 | 0.89 | 听 | 听 | 听 | (0.45 | ) |
| 听 | 听 | 听 | 听 | 听 | 听 | ||
| Weighted average common shares outstanding: Basic | 听 | 86,021,188 | 听 | 听 | 听 | 62,296,637 | 听 |
| Weighted average common shares outstanding: Diluted | 听 | 86,098,619 | 听 | 听 | 听 | 62,296,637 | 听 |
FAQ
What were Century Therapeutics' (IPSC) Q1 2025 financial results?
What is the status of CNTY-101 clinical trials for Century Therapeutics?
When will Century Therapeutics (IPSC) report clinical data for CNTY-101?
What happened to Century Therapeutics' collaboration with Bristol-Myers Squibb?
When will CNTY-308 enter IND-enabling studies?
